UPDATE : Thursday, April 18, 2019
Diabetic patients have higher risk of suffering from other illnesses
Researchers at Gangnam Severance Hospital have found that diabetes patients...
by Lee Han-soo  |  2019-04-18 16:02
CJ HealthCare’s new gastric acid blocker K-Cab sold ₩ 1.5 billion in March
CJ HealthCare’s K-Cab Tab., the nation’s 30th novel drug, recorded 1.53 bil...
by Jeong Sae-im  |  2019-04-18 15:27
‘No need to reduce number of drugs for triple-drug therapy to treat HIV’
In the past, HIV and AIDS were known as deadly diseases that could take awa...
by Kim Yun-mi  |  2019-04-18 15:20
Novartis’ new macular degeneration drug has to compete against colon cancer drug Avastin. Why?
Novartis’ new treatment for macular degeneration might have to fight agains...
by Kim Yun-mi  |  2019-04-18 14:42
‘How Korean pharma companies can succeed in US’
With most Korean pharmaceutical and biosimilar companies aiming to launch t...
by Lee Han-soo  |  2019-04-18 14:41
Kolon desperate to keep Invossa license amid suspicion of data fabrication
Kolon Life Science might get its sales license of Invossa-K revoked, as the...
by Lee Hye-seon  |  2019-04-18 11:16
IVI-led consortium wins Fleming Fund's grant
An international consortium led by the International Vaccine Institute (IVI...
by Lee Han-soo  |  2019-04-18 11:15
Severance Hospital succeeds in combined lung-liver transplant
Severance Hospital said Tuesday that it has successfully conducted a lung-l...
by Lee Han-soo  |  2019-04-17 18:00
Small drugmakers celebrate export deals worth ₩18.3 billion
The Ministry of Health and Welfare and the Korea Health Industry Developmen...
by Kwak Sung-sun  |  2019-04-17 17:20
THAAD backlash almost over: Chinese patients to Korea up 18 %
The number of Chinese patients visiting Korea rebounded in 2018, signaling ...
by Kwak Sung-sun  |  2019-04-17 16:00
Patients to file class-action suit against Kolon over Invossa
Local patients who got Invossa-K injection for arthritis treatment will pur...
by Jeong Sae-im  |  2019-04-17 14:58
‘Invossa lacked clinical evidence to be commercialized’
Kolon Life Science’s gene therapy Invossa-K for arthritis treatment had ina...
by Jeong Sae-im  |  2019-04-17 12:45
Shinpoong’s acute ischemic stroke treatment wins government support
Shinpoong Pharmaceutical said Tuesday that the Ministry of Food and Drug Sa...
by Lee Han-soo  |  2019-04-17 12:42
BIO KOREA 2019 aims to lead open innovation
BIO KOREA 2019 opened for a three-day run at COEX, southern Seoul, Wednesda...
by Lee Han-soo  |  2019-04-17 12:42
IVI gets $15.7 million to conduct P3 trials for Vi-DT typhoid conjugate vaccine
The International Vaccine Institute (IVI) said it has received a $15.7 mill...
by Lee Han-soo  |  2019-04-17 10:24
HIRA generates ₩35 billion worth economic value through international biz
The Health Insurance Review and Assessment Service (HIRA) said it has creat...
by Song Soo-youn  |  2019-04-16 16:19
Brexit to take toll on Korean medical device makers
“We are seriously concerned about no-deal Brexit. In the worst scenario, it...
by Park Gi-taek  |  2019-04-16 16:18
Celltrion unveils P2 trial results for influenza antibody therapy
Celltrion has presented the phase 2 clinical trial results for CT-P27, a co...
by Lee Han-soo  |  2019-04-16 16:16
Genexine’s immunotherapeutic drug candidate wins orphan drug status
Genexine and NeoImmuneTech said Tuesday that the U.S. Food and Drug Adminis...
by Lee Han-soo  |  2019-04-16 14:02
[Column] Measles and fake news
Health authorities are having a rough time unexpectedly because of measles ...
by Park Ji-wook  |  2019-04-16 14:02
Back to Top